APR's RF Microporation Boosts Minoxidil Skin Deposition 2.4x in Preclinical Hair Loss Study
核心洞察
APR (搜索) reported that its RF Microporation technology increased minoxidil deposition in the epidermis and dermis by up to 2.40 times versus minoxidil alone in preclinical animal models.
The industry-academia study, published in the Q1 journal Pharmaceutics, evaluated the Air Shot mode of APR (搜索)'s Medicube (搜索) Age-R Booster Pro X2 beauty device.
In androgenetic alopecia (搜索) animal models, combining RF Microporation with topical minoxidil significantly improved hair coverage, length and thickness.
South Korean beauty-tech company APR (搜索) announced on the 13th that a joint industry-academia research paper on combining topical minoxidil with its radiofrequency (RF) Microporation technology has been published in the international journal Pharmaceutics. The paper, published on the 28th of last month, reports that the technology increased minoxidil accumulation in the epidermis and dermis by up to 2.40 times compared with minoxidil applied alone in preclinical animal models.
Pharmaceutics is a Q1-ranked journal, placing it in the top 25% of pharmacology publications according to Journal Citation Reports (JCR). The study was conducted as a preclinical investigation using animal models.
Creating Microchannels in the Scalp
RF Microporation applies precisely controlled radiofrequency energy to the scalp's stratum corneum to create temporary microchannels. These channels allow topically applied active ingredients to penetrate deeper and in greater quantities into the inner layers of the skin and around hair follicles. The technology is featured in the Air Shot mode of APR (搜索)'s home beauty device, the Medicube (搜索) Age-R Booster Pro X2.
In animal models induced with androgenetic alopecia (搜索), researchers observed significant improvements not only in hair coverage but also in hair length and thickness when RF Microporation was applied in conjunction with topical minoxidil.
Topical hair loss treatments, including minoxidil, face a structural limitation: they must penetrate the stratum corneum, the outermost layer of the scalp, which makes it difficult for active ingredients to reach the skin and hair follicles in sufficient quantities. According to APR (搜索), RF Microporation addresses this by temporarily lowering the barrier to enhance drug delivery efficiency.
Potential Relevance for Female Pattern Hair Loss
The findings are especially noteworthy for patient populations with limited access to oral hair loss treatments. Finasteride, the active ingredient in Propecia—a leading treatment for male pattern baldness—is strictly restricted for use in women of childbearing age due to risks including fetal malformation in male fetuses. As a result, topical minoxidil applied directly to the scalp has become the de facto standard treatment for female pattern hair loss (搜索).
APR (搜索) explained that RF Microporation, by improving minoxidil's skin delivery, could offer an alternative that enhances treatment efficacy for patients who must rely primarily on topical therapies. The company said the significance of the technology lies in its potential to address the drug delivery limitations of existing topical hair loss treatments.
Platform Ambitions Beyond Minoxidil
APR (搜索) plans to expand the technology beyond minoxidil into a platform that facilitates absorption of various scalp and hair active ingredients. The stated vision is to develop it into a versatile technology spanning scalp environment management, hair health enhancement, and hair loss treatment. To this end, APR intends to conduct additional clinical research to verify efficacy and safety in the hair loss treatment field, aiming to secure sufficient clinical evidence and broaden the technology's scope in scalp and hair care.
"This publication in an international journal shows that we are continuously verifying the operating principles and efficacy of our own device technology scientifically, beyond simply developing products," an APR (搜索) official said. "We will continue to develop new technologies based on differentiated R&D competitiveness and work to introduce innovative products that apply them."
Preclinical Stage—Human Validation Still Pending
The study represents preclinical results from animal models. Hair loss treatment efficacy and safety in humans have not yet been confirmed, and additional clinical trials and regulatory approval procedures are required before the technology can be used for actual therapeutic purposes.
APR (搜索) has expanded its presence in the home beauty device market, centered on its Medicube (搜索) brand. The research findings have drawn industry attention for demonstrating the possibility that beauty device technology could extend beyond simple skincare into medically validated treatment-assistive applications. Interest is growing over whether accumulated clinical data could eventually lead to product development that blurs the boundary between beauty devices and hair loss treatment.